Fupeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fupeng Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abbas El Sahili
Nanyang Technological University
11 shared publications - Chuan-Fa Liu
School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
11 shared publications - Julien Lescar
Nanyang Technological University
11 shared publications - Keith Leong
Singzyme Pte. Ltd., Singapore, Singapore
11 shared publications - Seetharamsing Balamkundu
Singzyme Pte. Ltd., Singapore, Singapore
11 shared publications - Siew Pheng Lim
Novartis Institute for Tropical Diseases, Singapore
11 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Antibody–drug conjugates (ADC) are a rapidly expanding class of biopharmaceuticals for cancer-targeted therapy, with 15 ADCs approved for clinical use and more than a hundred candidates in clinical development. ADCs comprise a tumor-specific monoclonal antibody to which a cytotoxic payload is attached via a linker. Approved ADCs are heterogeneous products encompassing a range of drug-to-antibody ratios (DAR) due to the chemical methods employed for conjugation. Achieving precise DAR control is expected to improve product homogeneity, pharmacokinetics, safety, and clinical efficacy. In this study, we developed a rapid and efficient two-component bioconjugation system comprising a recombinant peptide asparaginyl ligase (PAL) and a human glutaminyl cyclase (hQC) to conjugate anti-HER2 antibodies. Trastuzumab and disitamab were conjugated with single or branched payloads, yielding ADCs with DAR values ranging from 2 to 8. These ADCs demonstrated cytotoxicity comparable with their chemically conjugated counterparts, trastuzumab deruxtecan (DXd, ENHERTU) and disitamab vedotin (Aidixi), against HER2-expressing breast cancer cell lines and Patient-Derived Xenograft (PDX) models. Notably, SGZ026, a PAL-conjugated trastuzumab DXd with a DAR of 3.9, exhibited better in vivo mouse plasma stability compared with ENHERTU (DAR 8). Despite carrying approximately half the cytotoxic payload per antibody, a single dose of SGZ026 effectively inhibited tumor growth in breast cancer PDX models with high or intermediate HER2 expression, achieving efficacy comparable with ENHERTU. These findings highlight a novel and robust enzyme-based conjugation technology for developing homogeneous ADCs with an improved therapeutic window.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Antibody–drug conjugates (ADC) are a rapidly expanding class of biopharmaceuticals for cancer-targeted therapy, with 15 ADCs approved for clinical use and more than a hundred candidates in clinical development. ADCs comprise a tumor-specific monoclonal antibody to which a cytotoxic payload is attached via a linker. Approved ADCs are heterogeneous products encompassing a range of drug-to-antibody ratios (DAR) due to the chemical methods employed for conjugation. Achieving precise DAR control is expected to improve product homogeneity, pharmacokinetics, safety, and clinical efficacy. In this study, we developed a rapid and efficient two-component bioconjugation system comprising a recombinant peptide asparaginyl ligase (PAL) and a human glutaminyl cyclase (hQC) to conjugate anti-HER2 antibodies. Trastuzumab and disitamab were conjugated with single or branched payloads, yielding ADCs with DAR values ranging from 2 to 8. These ADCs demonstrated cytotoxicity comparable with their chemically conjugated counterparts, trastuzumab deruxtecan (DXd, ENHERTU) and disitamab vedotin (Aidixi), against HER2-expressing breast cancer cell lines and Patient-Derived Xenograft (PDX) models. Notably, SGZ026, a PAL-conjugated trastuzumab DXd with a DAR of 3.9, exhibited better in vivo mouse plasma stability compared with ENHERTU (DAR 8). Despite carrying approximately half the cytotoxic payload per antibody, a single dose of SGZ026 effectively inhibited tumor growth in breast cancer PDX models with high or intermediate HER2 expression, achieving efficacy comparable with ENHERTU. These findings highlight a novel and robust enzyme-based conjugation technology for developing homogeneous ADCs with an improved therapeutic window.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 1. Analytic characterization of purified trastuzumab tagged with NQL tripeptide either at its light chain (panels A and B) or heavy chain (panels C and D) C-terminus, following SDS PAGE analysis (panels A and C) and size exclusion chromatography (panels B and D).
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 1. Analytic characterization of purified trastuzumab tagged with NQL tripeptide either at its light chain (panels A and B) or heavy chain (panels C and D) C-terminus, following SDS PAGE analysis (panels A and C) and size exclusion chromatography (panels B and D).
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data File from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
2 Supplementary Tables, 4 Schemes, Supplemental antibody sequences
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data File from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
2 Supplementary Tables, 4 Schemes, Supplemental antibody sequences
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 2A. Supplementary Figure 2A. Analysis by HIC of Trastuzumab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DARs) and payloads. Supplementary Figure 2B. Analysis of Disitamab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DAR) and payload types by HIC.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 2A. Supplementary Figure 2A. Analysis by HIC of Trastuzumab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DARs) and payloads. Supplementary Figure 2B. Analysis of Disitamab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DAR) and payload types by HIC.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 5. In vitro stability of SGZ230 vs Disitamab-MMAE in human plasma.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 5. In vitro stability of SGZ230 vs Disitamab-MMAE in human plasma.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 2B. Analysis of Disitamab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DAR) and payload types by HIC.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 2B. Analysis of Disitamab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DAR) and payload types by HIC.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 4. In vitro human and mouse plasma stabilities of SGZ002-LC-MMAE vs Kadcyla
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 4. In vitro human and mouse plasma stabilities of SGZ002-LC-MMAE vs Kadcyla
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 6. Mouse body weight change post-ADC treatment compared to vehicle control groups. (A-C) Mice were transplanted with HER2-expressing BT-474 cells and administered with a single intravenous dose of 1 mg/kg (A), 3 mg/kg (B), 10 mg/kg (C) of SGZ002-LC-MMAE, SGZ002-HC-MMAE or Kadcyla. (D-F) Mice were transplanted with HER2 (3+)-expressing PDX model, T226 and administered with a single intravenous dose of SGZ026 or Enhertu at 1 mg/kg (D), 3 mg/kg (E), or 7.5 mg/kg (F). (G-I) Mice were transplanted with HER2 (2+)-expressing PDX model, HBCx-1 and administered with a single intravenous dose of 10 mg/kg of SGZ022 or SGZ024 (G), SGZ230 or RC48 (Aidixi) (H), SGZ026 or Enhertu (I). Body weights were measured for up to 42 days (A-F) or 42 days (G-I).
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 6. Mouse body weight change post-ADC treatment compared to vehicle control groups. (A-C) Mice were transplanted with HER2-expressing BT-474 cells and administered with a single intravenous dose of 1 mg/kg (A), 3 mg/kg (B), 10 mg/kg (C) of SGZ002-LC-MMAE, SGZ002-HC-MMAE or Kadcyla. (D-F) Mice were transplanted with HER2 (3+)-expressing PDX model, T226 and administered with a single intravenous dose of SGZ026 or Enhertu at 1 mg/kg (D), 3 mg/kg (E), or 7.5 mg/kg (F). (G-I) Mice were transplanted with HER2 (2+)-expressing PDX model, HBCx-1 and administered with a single intravenous dose of 10 mg/kg of SGZ022 or SGZ024 (G), SGZ230 or RC48 (Aidixi) (H), SGZ026 or Enhertu (I). Body weights were measured for up to 42 days (A-F) or 42 days (G-I).
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 7. IC50 curves derived from in vitro cytotoxicity measurements of PAL-conjugated trastuzumab and disitamab ADCs, Aidixi and Enhertu against HER2-positive human breast cancer cells.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 7. IC50 curves derived from in vitro cytotoxicity measurements of PAL-conjugated trastuzumab and disitamab ADCs, Aidixi and Enhertu against HER2-positive human breast cancer cells.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 8. IC50 curves derived from in vitro cytotoxicity measurements of PAL-conjugated trastuzumab-Dxd (SGZ026 and SGZ028) and Enhertu against HER2-positive human breast cancer cells.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Antibody–Drug Conjugates Prepared with Peptide Asparaginyl Ligases Achieve Strong In Vitro and In Vivo Antitumor Activity
Supplementary Figure 8. IC50 curves derived from in vitro cytotoxicity measurements of PAL-conjugated trastuzumab-Dxd (SGZ026 and SGZ028) and Enhertu against HER2-positive human breast cancer cells.